Hsbc Holdings PLC Invests $7.07 Million in Xenon Pharmaceuticals Inc. $XENE

Hsbc Holdings PLC bought a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the first quarter, Holdings Channel.com reports. The fund bought 121,558 shares of the biopharmaceutical company’s stock, valued at approximately $7,069,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Avoro Capital Advisors LLC boosted its position in Xenon Pharmaceuticals by 0.5% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock worth $243,124,000 after purchasing an additional 24,444 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Xenon Pharmaceuticals by 3.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,084,034 shares of the biopharmaceutical company’s stock worth $183,110,000 after acquiring an additional 140,149 shares in the last quarter. Wellington Management Group LLP increased its holdings in Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after acquiring an additional 1,435,096 shares in the last quarter. Capital International Investors raised its position in Xenon Pharmaceuticals by 7.3% during the fourth quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock worth $153,058,000 after acquiring an additional 233,466 shares during the period. Finally, Commodore Capital LP lifted its holdings in Xenon Pharmaceuticals by 30.1% during the second quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after purchasing an additional 700,000 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insider Activity

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the transaction, the director owned 24,896 shares in the company, valued at $1,322,973.44. The trade was a 5.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director owned 1,455 shares in the company, valued at $77,318.70. The trade was a 44.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.91% of the stock is currently owned by corporate insiders.

Xenon Pharmaceuticals Trading Down 1.1%

NASDAQ XENE opened at $65.42 on Friday. The stock has a fifty day simple moving average of $58.08 and a 200-day simple moving average of $52.53. The stock has a market cap of $6.32 billion, a PE ratio of -13.92 and a beta of 0.61. Xenon Pharmaceuticals Inc. has a twelve month low of $30.00 and a twelve month high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same quarter in the previous year, the company earned ($0.83) earnings per share. Research analysts predict that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current year.

Analyst Upgrades and Downgrades

XENE has been the topic of several research analyst reports. Wells Fargo & Company reiterated an “overweight” rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Needham & Company LLC lowered their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Royal Bank Of Canada boosted their price target on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $77.20.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.